Increased CD36 expression has been shown to contribute to dyslipidemia and to be associated with insulin resistance and decreased glucose tolerance, suggesting that CD36 is involved in the physiopathology of insulin sensitivity. This evidence concerns the gene CD36 and metabolic syndrome.